Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

Wed, Sep 24

Perspectives

$IXHL's President & CEO, Joel Latham, spoke with @BenMComer of the Business of Biotech Podcast about developing #cannabinoid and psychedelic combination therapies for #sleepapnea, #rheumatoidarthritis, and generalized anxiety disorder. Listen here: https://t.co/LVlvMcOHy6 #IXHL

885158

On this weeks Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as...

Discover